Phase II Trial of Lutetium Lu 177 Dotatate in Advanced Bronchial Neuroendocrine Tumors
A phase II trial is evaluating lutetium Lu 177 dotatate against everolimus for advanced bronchial neuroendocrine tumors.
Therapeutic Area
Therapeutic area intelligence for Radioconjugate with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.